Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for AC Immune (ACIU : NSDQ)

• Company Description    AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland. Number of Employees: 122

• Price / Volume Information    Yesterday's Closing Price: $2.86 Daily Weekly Monthly 20 Day Moving Average: 246,025 shares Shares Outstanding: 101.77 (millions) Market Capitalization: $291.07 (millions) Beta: 1.60 52 Week High: $4.00 52 Week Low: $2.10 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 25.44% 26.00% 12 Week 22.22% 19.62% Year To Date -8.92% -19.22%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL EPFL INNOVATION PARK BUILDING B - LAUSANNE,V8 1015 CHE ph: 41-21-345-9121 fax: 41-21-345-9120 ir@acimmune.com http://www.acimmune.com

• General Corporate Information    Officers Andrea Pfeifer - Chief Executive Officer and Director Martin Zuegel - Chair and Director Christopher Roberts - Chief Financial Officer Roy Twyman - Director Carl June - Director Peer Information AC Immune (CORR.) AC Immune (RSPI) AC Immune (CGXP) AC Immune (BGEN) AC Immune (GTBP) AC Immune (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: H00263105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/03/26 Share - Related Items Shares Outstanding: 101.77 Most Recent Split Date: (:1) Beta: 1.60 Market Capitalization: $291.07 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.22 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.60 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/03/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.54 Price/Cash Flow: - Price / Sales: 13.14 EPS Growth vs. Year Ago Period: 112.00% vs. Previous Quarter: 115.79% Sales Growth vs. Year Ago Period: 1,108.66% vs. Previous Quarter: 1,239.01% ROE 06/30/26 - -100.17 03/31/26 - -125.26 12/31/25 - -103.15 ROA 06/30/26 - -28.36 03/31/26 - -40.85 12/31/25 - -39.10 Current Ratio 06/30/26 - 0.93 03/31/26 - 0.87 12/31/25 - 1.02 Quick Ratio 06/30/26 - - 03/31/26 - - 12/31/25 - 1.02 Operating Margin 06/30/26 - -245.32 03/31/26 - -1,788.02 12/31/25 - -1,977.71 Net Margin 06/30/26 - -245.32 03/31/26 - -1,788.02 12/31/25 - -1,977.71 Pre-Tax Margin 06/30/26 - - 03/31/26 - -1,796.18 12/31/25 - -1,971.48 Book Value 06/30/26 - 0.44 03/31/26 - 0.40 12/31/25 - 0.54 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.11 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 9.94 12/31/25 - 0.00

Powered by Zacks Investment Research ©